These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16049961)

  • 21. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome.
    Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
    Eur J Cancer; 2005 May; 41(7):1017-25. PubMed ID: 15862750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.
    Schmitz KJ; Otterbach F; Callies R; Levkau B; Hölscher M; Hoffmann O; Grabellus F; Kimmig R; Schmid KW; Baba HA
    Mod Pathol; 2004 Jan; 17(1):15-21. PubMed ID: 14631376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An immunohistochemical evaluation of phosphorylated Akt at threonine 308 [pAkt(Thr308)] in invasive breast cancer.
    Magkou C; Mylona E; Theohari I; Giannopoulou I; Papanikolaou E; Markaki S; Nakopoulou L
    In Vivo; 2007; 21(6):967-72. PubMed ID: 18210742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
    Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
    Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma.
    Yu L; Zhang J; Guo X; Li Z; Zhang P
    Cancer Epidemiol; 2014 Aug; 38(4):408-13. PubMed ID: 24923856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bad expression predicts outcome in patients treated with tamoxifen.
    Cannings E; Kirkegaard T; Tovey SM; Dunne B; Cooke TG; Bartlett JM
    Breast Cancer Res Treat; 2007 Apr; 102(2):173-9. PubMed ID: 17004114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast.
    Sastre-Garau X; Genin P; Rousseau A; Al Ghuzlan A; Nicolas A; Fréneaux P; Rosty C; Sigal-Zafrani B; Couturier J; Thiery JP; Magdelénat H; Vincent-Salomon A
    Histopathology; 2004 Aug; 45(2):142-7. PubMed ID: 15279632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
    Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables.
    Vasou O; Skagias L; Anastasia M; Paulina A; Patsouris E; Politi E
    Cytojournal; 2015; 12():6. PubMed ID: 25838835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
    Breast Cancer; 2015 Jan; 22(1):71-8. PubMed ID: 23479208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
    Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
    Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.
    Badve S; Collins NR; Bhat-Nakshatri P; Turbin D; Leung S; Thorat M; Dunn SE; Geistlinger TR; Carroll JS; Brown M; Bose S; Teitell MA; Nakshatri H
    Am J Pathol; 2010 May; 176(5):2139-49. PubMed ID: 20228224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The level of phosphorylated Akt predominantly reflects the expressive status of CerbB2 in invasive breast cancer.
    Chi Y; Zhao J; Cui SP; Jiang P; Wang HL; Zhang H; Mao JZ; Liu HJ; Hou L; Zhang B
    Histol Histopathol; 2013 May; 28(5):655-61. PubMed ID: 23420345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
    Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
    Bertucci F; Finetti P; Viens P; Birnbaum D
    Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.